A carregar...
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Today, glucagon‐like peptide‐1 (GLP‐1) receptor agonists are established glucose‐lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is...
Na minha lista:
| Publicado no: | J Diabetes Investig |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6400152/ https://ncbi.nlm.nih.gov/pubmed/30099845 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.12911 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|